scholarly journals Tumor-infiltrating lymphocytes are functionally inactivated by CD90+ stromal cells and reactivated by combined Ibrutinib and Rapamycin in human pleural mesothelioma

Theranostics ◽  
2022 ◽  
Vol 12 (1) ◽  
pp. 167-185
Author(s):  
Haitang Yang ◽  
Sabina Berezowska ◽  
Patrick Dorn ◽  
Philipp Zens ◽  
Peiru Chen ◽  
...  
Keyword(s):  
Stromal Cells ◽  
Tumor Infiltrating Lymphocytes ◽  
Pleural Mesothelioma ◽  
Infiltrating Lymphocytes

scholarly journals P3.03-012 Tumor-Infiltrating Lymphocytes, PDL-1, BAP-1, VEGFR-2 and IGF-1R Expression in Malignant Pleural Mesothelioma

2017 ◽  
Vol 12 (1) ◽  
pp. S1350-S1351
Author(s):  
Luca Ampollini ◽  
Letizia Gnetti ◽  
Matteo Goldoni ◽  
Nicoletta Campanini ◽  
Luigi Ventura ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Tumor Infiltrating Lymphocytes ◽  
Pleural Mesothelioma ◽  
Infiltrating Lymphocytes

scholarly journals CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection

2010 ◽  
Vol 59 (10) ◽  
pp. 1543-1549 ◽  
Author(s):  
Noriyuki Yamada ◽  
Satoshi Oizumi ◽  
Eiki Kikuchi ◽  
Naofumi Shinagawa ◽  
Jun Konishi-Sakakibara ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Tumor Infiltrating Lymphocytes ◽  
Pleural Mesothelioma ◽  
Favorable Prognosis ◽  
Infiltrating Lymphocytes

scholarly journals Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4+ tumor-infiltrating lymphocytes

2016 ◽  
Vol 5 (9) ◽  
pp. e1216289 ◽  
Author(s):  
Aikaterini Hatzioannou ◽  
Saba Nayar ◽  
Anastasios Gaitanis ◽  
Francesca Barone ◽  
Constantinos Anagnostopoulos ◽  
...  
Keyword(s):  
Lymph Node ◽  
Tumor Growth ◽  
Stromal Cells ◽  
Tumor Infiltrating Lymphocytes ◽  
Promote Tumor Growth ◽  
Infiltrating Lymphocytes ◽  
Lymph Node Stromal Cells

scholarly journals Spontaneous Regression of Malignant Pleural Mesothelioma, Possibly Caused by CD8+ Tumor-infiltrating Lymphocytes

Haigan ◽  
2021 ◽  
Vol 61 (2) ◽  
pp. 130-137
Author(s):  
Yosuke Kakiuchi ◽  
Hideshi Uramoto ◽  
Takaaki Ito ◽  
Sayuri Hirooka ◽  
Kazuyoshi Nakamura ◽  
...  
Keyword(s):  
Malignant Pleural Mesothelioma ◽  
Spontaneous Regression ◽  
Tumor Infiltrating Lymphocytes ◽  
Pleural Mesothelioma ◽  
Infiltrating Lymphocytes

Influence of a STAT3 inhibitor on tumor infiltrating lymphocytes in malignant pleural mesothelioma.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e23078-e23078 ◽  
Author(s):  
Seiji Matsumoto ◽  
Teruhisa Takuwa ◽  
Nobuyuki Kondo ◽  
Seiki Hasegawa
Keyword(s):  
Tumor Immunity ◽  
Malignant Pleural Mesothelioma ◽  
Transcriptional Activation ◽  
Untreated Control ◽  
Antitumor Effect ◽  
Tumor Infiltrating Lymphocytes ◽  
Pleural Mesothelioma ◽  
Cell Percentage ◽  
Cd8 Cell ◽  
Infiltrating Lymphocytes

e23078 Background: Patients with malignant pleural mesothelioma have elevated IL-6 levels in their blood and pleural fluid. IL-6 activates the JAK-STAT pathway and promotes transcriptional activation. Our previous work on a STAT3 inhibitor (BBI-608: napabucasin) as a molecular target drug for malignant pleural mesothelioma confirmed its antitumor effect. In this study, the effect of napabucasin on tumor immunity, specifically on tumor infiltrating lymphocytes, was evaluated. Methods: A mouse-derived malignant pleural mesothelioma cell line (AB22; 1.0 × 105 cells) was subcutaneously injected into BALB/cAJcl mice. When the tumors grew to 250 mm3, the mice were divided into three groups (five mice per group): untreated control, 5 mg/kg napabucasin, and 20 mg/kg napabucasin groups. The drug was orally administered twice daily. Tumor volumes were measured twice weekly, and the subcutaneous tumors were removed 15 days after treatment initiation. Tumor infiltrating lymphocytes were extracted from the tumors, and the CD8+ cell percentage was measured using FACS. Results: The subcutaneous tumors of the mice in the untreated control, 5 mg/kg napabucasin, and 20 mg/kg napabucasin groups grew to 2318 mm3, 1764 mm3, and 1383 mm3, respectively, after 15 days of treatment. Suppression of subcutaneous tumor growth was observed, and the inhibitory effect was greater in the 20 mg/kg than in the 5 mg/kg napabucasin groups. The CD8+ cell percentage of tumor infiltrating lymphocytes for the untreated control, 5 mg/kg napabucasin, and 20 mg/kg napabucasin groups was 8.6%, 6.9%, and 19.0%, respectively. The CD8+ cell percentage increased with the increase in drug dosage. Conclusions: We had previously confirmed the antitumor effect of napabucasin by STAT3 inhibition in malignant pleural mesothelioma. In this study, 20 mg/kg napabucasin increased the CD8+ cell percentage of tumor infiltrating lymphocytes, indicating that the drug appears to enhance tumor immunity and that it may be used in combination with an antitumor immune antibody.

Analysis of Tumor-infiltrating Lymphocytes Following CD45 Enrichment

BIO-PROTOCOL ◽  
2014 ◽  
Vol 4 (16) ◽  
Author(s):  
Rachel Perret ◽  
Sophie Sierro ◽  
Natalia Botelho ◽  
Stephanie Corgnac ◽  
Alena Donda ◽  
...  
Keyword(s):  
Tumor Infiltrating Lymphocytes ◽  
Infiltrating Lymphocytes
Sign in / Sign up

Export Citation Format

Share Document